title: Commentary: BMI and the need for adalimumab dose escalation in Crohn's disease.
authors.affiliation: Division of Gastroenterology, University Hospitals Leuven, Belgium. gert.vanassche@uzleuven.be
authors.forename: G
authors.initials: G
authors.lastname: Van Assche
authors.forename: F
authors.initials: F
authors.lastname: Baert
authors.forename: S
authors.initials: S
authors.lastname: Vermeire
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized